VivoSeq
Cardiovascular

Cardiac Surgery

0

Pipeline Programs

36

Active Trials

9

Companies Involved

Cardiac Surgery is an early-stage landscape with 0 programs across 9 companies. The most active players are Novartis, Action Pharma A/S, Guard Therapeutics AB.

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

37/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

264

clinical trials

Completed150 · 57%
Unknown status43 · 16%
Terminated23 · 9%
Recruiting18 · 7%
Not yet recruiting14 · 5%
Withdrawn11 · 4%
Other5 · 2%

Trial Activity

264 trials

Non-steroidal Anti-inflammatory in Cardiac Surgery
Recruiting··Phase 3·NCT06381063·238 enrolled
Prevent Cardiac Surgery Associated AKI Trial
Recruiting·GGeorge Washington University·Phase 2·NCT06620523·242 enrolled
Oral Methadone in Cardiac Surgery
Recruiting·MMayo Clinic·Phase 4·NCT07221617·100 enrolled
Intravenous Methadone for Sternotomy Pain Control in Cardiac Surgery
Recruiting··Phase 3·NCT06728371·86 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)